Thursday, March 23, 2017
Company News: Page (1) of 1 - 03/20/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Third Talcum Powder Lawsuit Verdict Stands, after Missouri Court Denies Johnson & Johnson Post-Trial Motions to Overturn $70 Million Judgment, Bernstein Liebhard LLP Reports
(March 20, 2017)

NEW YORK, March 20, 2017 /PRNewswire/ -- Johnson & Johnson and other talcum powder lawsuit defendants have been denied their bid to overturn the $70 million verdict awarded to the Plaintiff in the state's third ovarian cancer trial. In Orders issued last week, the Missouri 22nd Circuit Court in St. Louis denied all of the defendants' post-trial motions, including those that sought a judgment notwithstanding the verdict, a new trial, and a reduction in punitive damages. (Case No 1422-CC09012-01)

Bernstein Liebhard LLP.

"Our Firm has been retained by a number of women who allegedly developed ovarian cancer due to their long-term use of Johnson & Johnson's talc-based powders for feminine hygiene purposes. We are pleased that the verdict in this case was upheld, and are very encouraged with the Court's determination that the punitive damage award was 'not grossly excessive nor arbitrary,'" says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer that may be associated with long-term use of Johnson & Johnson's Baby Powder and Shower-to-Shower talc-based powders.

Talcum Powder Litigation

More than 3,000 talcum powder lawsuits have been filed in U.S. courts, all of which claim that the long-term genital application of Johnson & Johnson's products promotes the development of ovarian cancer. Missouri's third trial concluded last October, and involved a 62-year-old woman who was diagnosed with the disease in 2012. In the decades prior to her diagnosis, Johnson & Johnson's Baby Powder had been a regular part of the Plaintiff's daily feminine hygiene routine.

Missouri's 22nd Circuit Court has convened four talcum powder trials over the past year. Only one jury has found in favor of the defense. Plaintiffs in two other trials were awarded compensatory and punitive damages amounting to $72 million and $55 million.

Women who were diagnosed with ovarian cancer following the regular, repeated use of talc-based products for feminine hygiene purposes may be eligible to file their own talcum powder lawsuit. To learn more, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com


To view the original version on PR Newswire, visit:

SOURCE Bernstein Liebhard LLP

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:USA, Disease, Cancer, Technology, Surgery, Medication, Womens Health, Science, Medical Technology, Medical, Cancer, Other, Women,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • David A. Halsey MD, named first vice president of the American Academy of Orthopaedic Surgeons
  • Cryotherapy and Cryosurgery Market Rises High Incidence Of Cancer - IndustryARC
  • Global Radiology Oncology Surgical Robot Device Markets at $4 billion in 2015 are anticipated to reach $7.3 billion by 2022 - Acute Market Reports
  • FDA Approves Xadago® (Safinamide) for Parkinsons Disease (PD) Patients
  • Genomics Market Being Viewed As The Key To Achieving Human Immortality - IndustryARC Research

  • MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016
  • FREEMAXDESK Brings In BEST Power Adjustable Desk Converter At Rates To Fit Pockets
  • Global Automotive Ceramics Market Size, Share, Growth Rate and Forecast by 2022 - Market Research Report 2017
  • Marcus Theatres® To Host Inaugural CineLatino Milwaukee Film Festival At South Shore Cinema, April 27-30
  • FACIT Announces Investment in Propellon Therapeutics

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines